FDA Awards Destiny Pharma QIDP Designation for Staph Drug

November 17, 2015

Antimicrobial drugmaker Destiny Pharma has won qualified infectious disease product designation for its lead candidate XF-73 to prevent postsurgical staph infections, including multiple drug-resistant MRSA.

Phase 1/2a studies conducted in Europe show the compound reduces the number of bacteria in the nose quickly. XF-73 (exeporfinium chloride) is being studied in a clinical trial sponsored by NIH’s National Institute of Allergy and Infectious Diseases that is expected to be completed shortly.